CrossRef 10 Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JE

CrossRef 10. Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JE, Kuhl J, Demaerel P, Warmuth-Metz M, Flamen P, Van Calenbergh F, Plets C, Sorensen N, Opitz A, Van Gool SW: Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Canc 2004, 91:1656–1662. 11. Novoselov KS, Geim AK, Morozov SV, Jiang D, Zhang Y, Dubonos SV, Grigorieva IV, Firsov AA: Electric field effect in atomically thin carbon films. Science 2004, 306:666–669.CrossRef 12. Liu

Z, Robinson JT, Sun XM, Dai HJ: PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc 2008, 130:10876–10877.CrossRef 13. Sun XM, Liu Z, Welsher K, Robinson JT, Goodwin A, Zaric S, Dai HJ:

Nano-graphene oxide for cellular imaging and drug delivery. Nano Res 2008, 1:203–212.CrossRef 14. Wang Y, Li Z, Hu D, Lin CT, Rho inhibitor Li J, Lin Y: Aptamer/graphene oxide nanocomplex for in situ molecular probing in living cells. J Am Chem Soc 2010, 132:9274–9276.CrossRef 15. Bao H, Pan Y, Ping Y, Sahoo NG, Wu T, Li L, Li J, Gan LH: Chitosan-functionalized graphene oxide as a nanocarrier for drug and gene delivery. Small 2011, 7:1569–1578.CrossRef Epigenetics inhibitor 16. Geim AK, Novoselov KS: The rise of graphene. Nat Mater 2007, 6:183–191.CrossRef 17. Yang XY, Zhang XY, Liu ZF, Ma YF, Huang Y, Chen Y: High-efficiency loading and controlled release of doxorubicin hydrochloride on graphene oxide. J Phys Chem C 2008, 112:17554–17558.CrossRef 18. Yang K, Zhang S, Zhang G, Sun X, Lee ST, Liu Z: Graphene in mice: ultrahigh in vivo tumor uptake Non-specific serine/threonine protein kinase and efficient photothermal therapy. Nano Lett 2010, 10:3318–3323.CrossRef

19. Li Y, Wu Q, Zhao Y, Bai Y, Chen P, Xia T, Wang D: Response of microRNAs to in vitro treatment with graphene oxide. ACS Nano 2014, 8:2100–2110.CrossRef 20. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, Loeffler JS: Quantitatively determined AC220 purchase survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002, 20:1063–1068.CrossRef 21. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K, Kurisu K: Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 2003, 97:1077–1083.CrossRef 22. Xie D, Zeng YX, Wang HJ, Wen JM, Tao Y, Sham JS, Guan XY: Expression of cytoplasmic and nuclear survivin in primary and secondary human glioblastoma. Br J Canc 2006, 94:108–114.CrossRef 23. Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, Wepsic HT, Okada H, Jadus MR: Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Canc Res 2007, 13:566–575.CrossRef 24. Kovtyukhova NI, Ollivier PJ, Martin BR, Mallouk TE, Chizhik SA, Buzaneva EV, Gorchinskiy AD: Layer-by-layer assembly of ultrathin composite films from micron-sized graphite oxide sheets and polycations. Chem Mater 1999, 11:771–778.CrossRef 25.

Comments are closed.